Altering The Transition From Acute to Chronic Pain (ATTAC-Pain)
Status:
Completed
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
The current way that pain is treated after trauma and injury is problematic. Most often pain
after trauma is treated with opioids (ex. Percocet® or Vicodin®) or anti-inflammatories (ex.
ibuprofen). Both of these medications can cause side effects and opioids have been related to
the development of addiction. In addition, there are not any treatments that prevent pain
from going on to become persistent (last beyond it is supposed to) or chronic (lasting 3
months or longer).
Chronic pain is an enormous problem and there an urgent need to find both alternatives to
opioid pain medications and medications that prevent pain from becoming chronic. The
ATTAC-Pain (Altering The Transition from Acute to Chronic Pain) study proposes to examine
whether duloxetine (a medication that is marketed for depression, anxiety, and specific types
of pain conditions), can reduce acute and chronic pain among adults who come to the emergency
department (ED)with muscular pain (such as neck pain after a car accident or low back pain).
Investigators will enroll 60 patients who come to the ED. Patients will be eligible if they
report moderate to severe muscular pain (such as pain in the back, neck, or shoulders).
Consenting patients will be randomized to receive duloxetine 30mg, duloxetine 60mg, or
placebo (2/3rd chance of being in one of the duloxetine groups). The study team will follow
patients for six weeks and collect information on pain outcomes and use of pain medications.
Investigators aim to determine if duloxetine can (1) reduce acute pain symptoms following the
ED visit, (2) prevent the transition to persistent pain (having pain 6 weeks after the
initial ED visit), and (3) decrease opioid use following a motor vehicle collision (MVC). The
results of this study will ultimately help determine if duloxetine can be used as a
non-opioid pain treatment option that reduces acute pain and prevents the transition to
chronic pain. This in turn can improve recovery, reduce opioid use and its consequences, and
decrease health care costs.
Phase:
Phase 2
Details
Lead Sponsor:
Rhode Island Hospital
Collaborators:
Mayday Fund National Institute of General Medical Sciences (NIGMS)